SCHEMBL1206331

SCHEMBL1206331

CCCN(CCC)CCCCNS(=O)(=O)c1ccc(CN)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.50
TSHR P16473 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
CA9 Q16790 3/20 0.47
CA12 O43570 2/20 0.47
CA2 P00918 2/20 0.47
CA1 P00915 1/20 0.47
TPSAB1 Q15661 2/20 0.46
SIGMAR1 Q99720 2/20 0.46
ALDH1A1 P00352 2/20 0.46
PKM P14618 2/20 0.46
LMNA P02545 2/20 0.45
HTT P42858 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALOX15 P16050 1/20 0.45
GHSR Q92847 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PSIP1 O75475 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3324244 0.82 USP2 (0.57) USP2TSHRTDP1CA9CA12
SCHEMBL3382625 0.80 USP2 (0.54) USP2TSHRTDP1CA9CA12
SCHEMBL23718102 0.80 CA12 (0.61) USP2CA9CA12CA2SIGMAR1
SCHEMBL1204483 0.78 CA12 (0.49) USP2TSHRTDP1CA9CA12
SCHEMBL13117941 0.77 TSHR (0.67) TSHRCA9CA12CA2CA1
SCHEMBL3322296 0.77 USP2 (0.61) USP2TSHRTDP1CA9CA12
SCHEMBL3387798 0.77 SIGMAR1 (0.54) USP2TSHRTDP1CA9CA12
SCHEMBL3387197 0.76 USP2 (0.57) USP2TSHRTDP1CA9CA12
SCHEMBL1205260 0.76 CXCR4 (0.53) USP2TSHRTDP1SIGMAR1ALDH1A1
SCHEMBL7042308 0.76 MEN1 (0.56) USP2TSHRTDP1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-02-24 US disclosed
US-7833991-B2 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2010-11-16 US disclosed
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2007-09-06 US disclosed
US-7176227-B2 For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis KUREHA CORPORATION (JP) 2007-02-13 US disclosed
US-20050165063-A1 Amine compounds and use thereof KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) 2005-07-28 US disclosed
EP-1550657-A1 AMINE COMPOUNDS AND USE THEREOF Kureha Chemical Industry Co., Ltd. (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165063-A1 Amine compounds and use thereof NR0B2, NR5A2, NR1H4 USP2 4594/4885TSHR 1027/4885TDP1 4143/4885
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF NR0B2, NR1D2, NR0B1 USP2 4592/4885TSHR 811/4885TDP1 4336/4885
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists CXCR4, CXCR6, CCR5 USP2 4401/4885TSHR 1516/4885TDP1 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.